BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $119.00 at Morgan Stanley

Key Points

• Morgan Stanley lowered its price target on BioMarin from $120 to $119 but kept an "overweight" rating, implying roughly a 120% upside from the current share price (~$54).
• Q1 results were mixed: revenue beat and full‑year revenue guidance was raised to $3.825B–$3.925B, yet Q1 EPS of $0.76 missed estimates and FY EPS guidance of $4.85–$5.05 was slightly below Street expectations.
• Insider selling noted: two executive VPs sold shares (16,486 and 6,326 shares), reducing their holdings and leaving company insiders with about 0.85% ownership.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its price objective cut by equities research analysts at Morgan Stanley from $120.00 to $119.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an "overweight" rating on the biotechnology company's stock. Morgan Stanley's price objective indicates a potential upside of 120.24% from the company's current price.

BMRN has been the subject of several other reports. Stifel Nicolaus set a $68.00 target price on BioMarin Pharmaceutical in a research note on Tuesday, February 24th. Wells Fargo & Company raised their target price on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Jefferies Financial Group reiterated a "buy" rating and issued a $103.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. Canaccord Genuity Group lifted their price target on BioMarin Pharmaceutical from $98.00 to $104.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Finally, Barclays lifted their price target on BioMarin Pharmaceutical from $80.00 to $105.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus target price of $90.86.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN traded down $1.43 during midday trading on Tuesday, reaching $54.03. 1,325,501 shares of the stock were exchanged, compared to its average volume of 2,004,270. BioMarin Pharmaceutical has a twelve month low of $50.76 and a twelve month high of $66.28. The business's 50-day moving average price is $56.93 and its 200 day moving average price is $56.32. The company has a market capitalization of $10.44 billion, a price-to-earnings ratio of 30.35, a PEG ratio of 0.54 and a beta of 0.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.21 and a quick ratio of 3.50.

Insider Transactions at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of the firm's stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total value of $996,743.56. Following the transaction, the executive vice president owned 79,953 shares of the company's stock, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gregory R. Friberg sold 6,326 shares of the firm's stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the transaction, the executive vice president directly owned 37,578 shares in the company, valued at $2,268,959.64. This represents a 14.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.85% of the company's stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds have recently made changes to their positions in the business. Activest Wealth Management bought a new stake in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $26,000. Quent Capital LLC bought a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at approximately $28,000. CIBC Private Wealth Group LLC raised its holdings in shares of BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company's stock valued at $39,000 after buying an additional 179 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 92.5% during the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company's stock valued at $40,000 after buying an additional 360 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of BioMarin Pharmaceutical during the third quarter valued at approximately $40,000. Institutional investors own 98.71% of the company's stock.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q1 revenue beat estimates and company raised full‑year revenue guidance to $3.825B–$3.925B, citing portfolio additions (GALAFOLD®, POMBILITI® + OPFOLDA®) as growth drivers — this supports longer‑term top‑line growth expectations. PR Newswire: BioMarin Reports First Quarter 2026 Financial and Operating Results
• Positive Sentiment: Royal Bank of Canada reaffirmed its "sector perform" rating and set a $66 price target (~21% upside from current levels), which could provide analyst‑driven support if sentiment improves. TickerReport / Benzinga: RBC reaffirms rating, $66 PT
• Neutral Sentiment: HC Wainwright reaffirmed a "neutral" rating with a $55 price target — little change to sell‑side consensus and a reminder of mixed analyst views. TickerReport / Benzinga: HC Wainwright reaffirmation
• Neutral Sentiment: Full Q1 earnings call transcript and slide deck are available for details on drivers and margin outlook; these materials may clarify management's path to margin improvement. Seeking Alpha: Q1 2026 earnings call transcript
• Negative Sentiment: Q1 EPS of $0.76 missed the Zacks consensus of $0.94 and fell year‑over‑year, a clear near‑term earnings disappointment that weighs on valuation multiples. Zacks: Q1 earnings lag estimates
• Negative Sentiment: FY EPS guidance was set at $4.85–$5.05 vs. a Street consensus near $4.98 — a mild shortfall that, combined with the EPS miss, increases near‑term investor caution despite revenue upside. BioMarin Q1 press materials (slide deck / press release)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.